Cervarix

http://doxymu.no-ip.org/lodac/
cervarix

Learn more about Cervarix, an HPV vaccine that is projected to be approved by the FDA in the fall of 2006. Cervarix offers an alternive to Gardasil, the HPV vaccine already
Cervarix - Patient Information Leaflet (PIL) by GlaxoSmithKline UK The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
Cervarix , Summary of Product Characteristics (SPC) from the eMC
This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
Cervarix™, GSK's HPV 16/18 Cervical Cancer Vaccine is highly immunogenic and well tolerated in women over 25 years of age An AS04-containing human papillomavirus (HPV) 16/18
CERVARIX is a vaccine used in females from 10 to 45 years of age to prevent early stage cervical cancers (pre-cancerous lesions), pap smear abnormalities and cervical cancer caused
A second HPV vaccine, Cervarix™, produced by GlaxoSmithKline, is in Phase III clinical trials The vaccine is designed to protect against infection by HPV types 16 and 18, these
Results from an interim analysis of a Phase III study show that <i>Cervarix,</i> the GlaxoSmithKline cervical cancer candidate vaccine, provides up to 100% protection against
Research Investment Choices. Explore Cervarix Now!
Learn about Cervarix, an experimental HPV vaccine that may compete with Gardasil.

Helvellyn